We are working closely with the FDA to bring this additional Nubeqa treatment option to patients as soon as possible.” Bayer’s 2023 financial report detailed how therapy generated €869m ($ ...

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 ...

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson, and fulfil ...

Bayer BAYRY announced that the FDA has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide). The sNDA is seeking label expansion of Nubeqa in combination with androgen ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.Da3GqCks.js ...

Finance, Bayer’s market cap has fallen more than ... streamlining structures in the pharma division accelerated the launch of Nubeqa - a drug that’s already generated over $1 billion USD.

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

head of Bayer’s pharma division, said Tuesday at the J.P. Morgan Healthcare Conference. Besides label expansions for in-market products such as prostate cancer drug Nubeqa and kidney disease ...

Bayer recently submitted an application to the ... in addition to filings in the U.S. and the EU earlier in 2024. NUBEQA achieved global blockbuster status in September 2024 after crossing the ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...